Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH

Phase 3

Completed

Conditions: Benign Prostatic Hyperplasia

First Posted Date: 2006-07-04

Last Posted Date: 2009-10-02

Lead Sponsor: Sanofi

Target Recruit Count: 148

Registration Number: NCT00347061

Locations: 🇯🇵
Sanofi-Aventis, Tokyo, Japan

Insulin Glargine in Type 2 Diabetic Patients

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine
Drug: Glyburide
Drug: Metformin
Drug: Glyclazide
Drug: Glimiperide
Drug: Glipizide

First Posted Date: 2006-07-04

Last Posted Date: 2009-09-15

Lead Sponsor: Sanofi

Target Recruit Count: 387

Registration Number: NCT00347100

Locations: 🇨🇳
Sanofi-Aventis, Beijing, China

HENOX: Enoxaparine in Hemodialysis

Phase 4

Completed

Conditions: Hemodialysis

First Posted Date: 2006-07-04

Last Posted Date: 2008-01-24

Lead Sponsor: Sanofi

Target Recruit Count: 100

Registration Number: NCT00347490

Locations: 🇹🇭
Sanofi-Aventis, Bangkok, Thailand

Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia

Phase 2

Completed

Conditions: Obesity
Dyslipidemia

First Posted Date: 2006-06-28

Last Posted Date: 2008-12-19

Lead Sponsor: Sanofi

Target Recruit Count: 345

Registration Number: NCT00345410

Locations: 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Risedronate in Osteopenic Postmenopausal Women

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: risedronate
Drug: risedronate placebo

First Posted Date: 2006-06-28

Last Posted Date: 2009-12-07

Lead Sponsor: Sanofi

Target Recruit Count: 156

Registration Number: NCT00345644

Locations: 🇫🇷
Sanofi-Aventis, Paris, France

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

Phase 3

Completed

Conditions: Thrombosis
Embolism

Interventions: Drug: Idrabiotaparinux sodium
Drug: Warfarin
Drug: Avidin
Drug: Placebo (for idrabiotaparinux sodium)
Drug: Placebo (for warfarin)
Drug: Enoxaparin

First Posted Date: 2006-06-28

Last Posted Date: 2016-03-21

Lead Sponsor: Sanofi

Target Recruit Count: 3202

Registration Number: NCT00345618

Locations: 🇷🇺
Sanofi-Aventis Admnistrative Office, Moscow, Russian Federation
🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia

and more 1 locations